These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32865979)

  • 1. Hepatocellular Carcinoma and Statins.
    Alipour Talesh G; Trézéguet V; Merched A
    Biochemistry; 2020 Sep; 59(37):3393-3400. PubMed ID: 32865979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of statins in the diseases of the liver.
    Janicko M; Drazilova S; Pella D; Fedacko J; Jarcuska P
    World J Gastroenterol; 2016 Jul; 22(27):6201-13. PubMed ID: 27468210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection.
    Kawaguchi Y; Sakamoto Y; Ito D; Ito K; Arita J; Akamatsu N; Kaneko J; Hasegawa K; Moriya K; Kokudo N
    Biosci Trends; 2017 Nov; 11(5):574-580. PubMed ID: 29081488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Role for Statins in Palliative Care for Patients Suffering from Hepatocellular Carcinoma?
    Björkhem-Bergman L
    J Palliat Care; 2015; 31(3):172-6. PubMed ID: 26514023
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential for statins in the chemoprevention and management of hepatocellular carcinoma.
    Lonardo A; Loria P
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1654-64. PubMed ID: 22849701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of statins in treating liver disease.
    Imprialos KP; Stavropoulos K; Doumas M; Skalkou A; Zografou I; Athyros VG
    Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):331-339. PubMed ID: 29431526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
    Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
    Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
    Sutter AP; Maaser K; Höpfner M; Huether A; Schuppan D; Scherübl H
    J Hepatol; 2005 Nov; 43(5):808-16. PubMed ID: 16083991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
    Goh MJ; Sinn DH
    Clin Mol Hepatol; 2022 Jul; 28(3):380-395. PubMed ID: 35021597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins in liver disease: a molehill, an iceberg, or neither?
    Argo CK; Loria P; Caldwell SH; Lonardo A
    Hepatology; 2008 Aug; 48(2):662-9. PubMed ID: 18666246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma.
    Wang Y; Wang W; Wang M; Shi J; Jia X; Dang S
    Can J Gastroenterol Hepatol; 2022; 2022():5389044. PubMed ID: 35356132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
    Kah J; Wüstenberg A; Keller AD; Sirma H; Montalbano R; Ocker M; Volz T; Dandri M; Tiegs G; Sass G
    Oncol Rep; 2012 Sep; 28(3):1077-83. PubMed ID: 22710979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms.
    Kim G; Kang ES
    Semin Liver Dis; 2019 May; 39(2):141-152. PubMed ID: 30912095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality.
    Thrift AP; Natarajan Y; Liu Y; El-Serag HB
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2117-2125.e3. PubMed ID: 30625400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
    Sharpton SR; Loomba R
    Hepatology; 2023 Dec; 78(6):1896-1906. PubMed ID: 37013380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and cancer.
    Vallianou NG; Kostantinou A; Kougias M; Kazazis C
    Anticancer Agents Med Chem; 2014 Jun; 14(5):706-12. PubMed ID: 24295174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.